Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of Oral Epalrestat Therapy in Pediatric Subjects With Phosphomannomutase 2-congenital Disorder of Glycosylation (PMM2-CDG)

NCT04925960 is registered in ClinicalTrials.gov with Maggie's Pearl, LLC as lead sponsor.

NCT NCT04925960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04925960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of Oral Epalrestat Therapy in Pediatric Subjects With Phosphomannomutase 2-congenital Disorder of Glycosylation (PMM2-CDG)
Lead sponsor
Maggie's Pearl, LLC
Phase
Phase 3
Overall status
Terminated
Start date
November 10, 2022
Completion date
February 28, 2025
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

phosphomannomutase 2 congenital disorder of glycosylation, phosphomannomutase 2 deficiency, phosphomannomutase ii congenital disorder of glycosylation, phosphomannomutase ii deficiency, pmm2-cdg